pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·Aug 11·1 min read
save

PIC/S releases revised guide on qualification and validation studies for pharma manufacturing

Aug 11, 2026·read at raps ↗RegulatoryNeutral

PIC/S has issued an updated guideline that outlines general principles for qualification and validation studies in pharmaceutical manufacturing facilities.

The new guide is intended for both inspectors and industry stakeholders, providing clearer expectations on how to design, conduct, and document qualification and validation activities.

Adoption of the revised guidance aims to harmonize practices across member countries and support consistent compliance with good manufacturing standards.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “PIC/S updates guideline on process qualification and validation studies”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2d agoThis Week at FDA: Overton confirmation hearing, animal testing rule, and moreraps
  • 2d agoRecon: Adcomm backs Grail’s cancer test; Lilly, China’s InnoCare sign $3.35B dealraps
  • 2d agoEuro Roundup: EMA officials argue against making single pivotal trials the ‘rigid, default position’raps
  • 2d agoFDA nominee Overton faces grilling in Senate confirmation hearingraps
  • 2d agoConvergence: Thinking past GCP compliance for regulatory acceptability of foreign trial dataraps